Impact of cerebrospinal fluid leukocyte infiltration and activated neuroimmune mediators on survival with HIV-associated cryptococcal meningitis

PLoS Negl Trop Dis. 2025 Feb 10;19(2):e0012873. doi: 10.1371/journal.pntd.0012873. eCollection 2025 Feb.

Abstract

Introduction: Cryptococcal meningitis remains a prominent cause of death in persons with advanced HIV disease. CSF leukocyte infiltration predicts survival at 18 weeks; however, how CSF immune response relates to CSF leukocyte infiltration is unknown.

Methods: We enrolled 401 adults with HIV-associated cryptococcal meningitis in Uganda who received amphotericin and fluconazole induction therapy. We assessed the association of CSF leukocytes, chemokine, and cytokine responses with 18-week survival.

Results: Participants with CSF leukocytes ≥50/microliter had a higher probability of 18-week survival compared with those with ≤50 cells/microliter (68% (52/77 vs. 52% (151/292); Hazard Ratio = 1.63, 95% confidence interval 1.14-2.23; p = 0.008). Survival was also associated with higher expression of T helper (Th)-1, Th17 cytokines, and immune regulatory elements. CSF levels of Programmed Death-1 Ligand, CXCL10, and Interleukin (IL)-2 independently predicted survival. In multivariate analysis, CSF leukocytes were inversely associated with CSF fungal burden and positively associated with CSF protein and immune parameters (interferon-gamma (IFN-γ), IL-17A, tumor necrosis factor alpha (TNF)-α, and circulating CD4+ and CD8+ T cells).

Conclusion: 18-week survival after diagnosis of cryptococcal meningitis was associated with higher CSF leukocytes at baseline with greater T helper 1 (IFN-γ, IL-2 and TNF-α cytokines), T helper 17 (IL-17A cytokine) and CXCR3+ T cell (CXCL10 chemokine) responses. These results highlight the interdependent contribution of soluble and cellular immune responses in predicting survival and may support potential pathways for adjunctive immune therapy in HIV-associated cryptococcal meningitis.

MeSH terms

  • Adult
  • Antifungal Agents / therapeutic use
  • Cerebrospinal Fluid* / cytology
  • Cerebrospinal Fluid* / immunology
  • Cytokines / cerebrospinal fluid
  • Female
  • Fluconazole / therapeutic use
  • HIV Infections* / complications
  • HIV Infections* / immunology
  • Humans
  • Leukocytes* / immunology
  • Male
  • Meningitis, Cryptococcal* / cerebrospinal fluid
  • Meningitis, Cryptococcal* / drug therapy
  • Meningitis, Cryptococcal* / immunology
  • Meningitis, Cryptococcal* / mortality
  • Middle Aged
  • Survival Analysis
  • Uganda
  • Young Adult

Substances

  • Cytokines
  • Antifungal Agents
  • Fluconazole